Skip to main content

Why CDK4/6 Inhibitors Are Effective in HR-Positive Metastatic Breast Cancer

Videos
Hope S. Rugo, MD
Professor of Medicine and Winterhof Family Professor of Breast Oncology
University of California San Francisco Comprehensive Cancer Center
San Francisco, CA

Dr Hope Rugo cites that CDK4/6 inhibitors play a critical role in estrogen signaling and can be very effective in treating metastatic breast cancer when used in combination with hormone therapy.

Related Items